Could a new drug save pregnancies in High-Risk women?

NCT ID NCT03152058

First seen Apr 07, 2026 · Last updated Apr 28, 2026 · Updated 5 times

Summary

This study tests whether adding certolizumab to standard treatment (blood thinners and aspirin) can prevent serious pregnancy complications like fetal death or early delivery in pregnant women with antiphospholipid syndrome (APS) who have a specific blood clotting problem. About 55 high-risk pregnant women will receive the drug, and their outcomes will be compared to similar women from a previous study. The goal is to improve pregnancy success rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital for Special Surgery

    RECRUITING

    New York, New York, 10021, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • TRIO Advancing Reproductive Care

    RECRUITING

    Toronto, Ontario, M5G 2K4, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Utah

    RECRUITING

    Salt Lake City, Utah, 84132, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.